Home Your basket
• Setting up a «Bonebridge»...
   Price 10.50 €
• Otomycosis...
   Price 10.50 €
• Endoscopic ligation of th...
   Price 12.00 €
• Progressive cochleo-vesti...
   Price 5.50 €
• The ultra-rapid cinematog...
   Price 10.50 €
• Synovial sarcoma of the h...
   Price 5.50 €
• Management of cervical ce...
   Price 10.50 €
• Transhyoid bucopharyngect...
   Price 8.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Conference : Medicine of ...
   Price 5.50 €
• Recurrences of pleomorphi...
   Price 10.50 €
• Chronitis tonsillitis...
   Price 8.50 €
• Validation of a self-asse...
   Price 10.50 €
• Saddle nose surgery: Long...
   Price 10.50 €
• Planned reconstruction af...
   Price 8.50 €
• Functional results of vel...
   Price 5.50 €
• Invasive cholesteatoma in...
   Price 10.50 €
• Is HIV/AIDS an independen...
   Price 10.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• Management of respiratory...
   Price 14.00 €
• Aneurysmal bone cyst of t...
   Price 5.50 €
• Botulinum toxin, descript...
   Price 12.50 €
• Migrating hypopharyngeal ...
   Price 5.50 €
• Laryngeal cryptococcosis ...
   Price 8.50 €
• Spontaneous subcutaneous ...
   Price 5.50 €
• Ectopic thyroid: A report...
   Price 8.50 €
• Merkel cell carcinoma of ...
   Price 8.50 €
• Teeth and sinuses...
   Price 8.50 €
• Vestibular dysfunction af...
   Price 10.50 €
• Hearing aid : practical a...
   Price 8.50 €
• Determination of oesophag...
   Price 10.50 €
• Interstitial brachytherap...
   Price 8.50 €

Total Order 280.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 3 - 2017 o

OTOLOGY

Observational study to assess the effect of Audistim® on the quality of life of patients presenting with chronic tinnitus


Authors : Frachet B, Portmann D, Allaert FA. (Paris, Bordeaux, Dijon)

Ref. : Rev Laryngol Otol Rhinol. 2017;138,3:79-85.

Article published in english
Downloadable PDF document english



Summary : Objectives: To evaluate the improvement of symptoms, quali­ty of life, psychological stress and sleep quality of patients suffering from chronic tinnitus after a 3 months intake of Audistim®. Methods: Observational study of Audistim® by ENT doctors in patients consulting them for chronic tinnitus. Evaluation criterion: THI quality of life score, PSQI sleep score, MSP-9 Stress score. Patients were examined at baseline and at 3 months. Results: 314 patients aged 54.1 ± 13.0 years and suffering from tinnitus since 5.8 ± 7.3 years were included in the study. At the end of the 3 months, patients’ quality of life chan­­ged from 44.6 ± 23.4 to 26.7 ± 18.7 corresponding to an impro­vement of 40.1% (< 0.0001), subjects’ stress from 38.5 ± 13.3 to 30.1 ± 10.8 to 3 months corresponding to an improve­ment of 21.8% (<0.0001) and sleep quality of 8.4 ± 4.5 to 5.4 ± 3.2 corresponding to an improvement of 35.7%. Quality of life improvement was significantly correlated with stress impro­vement (r: 0.77 (p< 0.0001) and sleep (r: 0.70 (p< 0.0001). Tinnitus were improved in 70.0% of patients according to doc­tors, and in 69% of them according to the patients themselves. 2.8% of patients experienced adverse events, essentially diges­tive, none of which was judged by doctors as imputable to the intake of Audistim®. Conclusion: The original composition of Audistim® combining several active ingredients used to control tinnitus gives rise to clear improvements in the quality of life, stress and sleep of the patients experiencing tinnitus and provides them satisfaction without the risk of adverse events.


Price : 14.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE